Evaxion Announces Business Update and Second Quarter 2024 Financial Results
14 août 2024 07h00 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
12 août 2024 07h27 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
08 août 2024 08h00 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
16 juil. 2024 07h30 HE
|
Evaxion Biotech
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art...
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
03 juil. 2024 08h05 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
26 juin 2024 07h30 HE
|
Evaxion Biotech
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the inventionUnique Attributes and...
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
17 juin 2024 08h44 HE
|
Evaxion Biotech
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic...
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
03 juin 2024 08h00 HE
|
Evaxion Biotech
Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 mai 2024 08h21 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
23 mai 2024 17h00 HE
|
Evaxion Biotech
EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both...